Shots: The P-III head-to-head ELEVATE-RR trial evaluating Calquence (100mg, PO, bid) vs ibrutinib (420mg, PO, qd) in a ratio (1:1) in 533 patients with previously treated CLL The trial met […]readmore
Shots: The P-ll CALAVI programme involves assessing Calquence + BSC vs BSC as monothx. in patients in a ratio (1:1) hospitalized with respiratory complications of COVID-19 in the ratio of […]readmore
Shots: The CALAVI program involves assessing of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19, but not on assisted ventilation. The studies are […]readmore
Shots: The CALAVI study is a two-part trial assessing the efficacy and safety of Calquence + BSC vs BSC as monothx. in patients hospitalized with respiratory complications of COVID-19 Part […]readmore
Shots: The P-III ELEVATE TN study involves assessing of Calquence + obinutuzumab / Calquence as monothx. vs chlorambucil + obinutuzumab in 535 patients in a ratio (1:1:1) with previously untreated […]readmore
Shots: The US FDA in collaboration with TGA and Health Canada granted supplemental approval to AstraZeneca’s Calquence to treat patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), […]readmore
Shots: The NOC is based on the positive data of Calquence in ACE-LY-004 trial demonstrating 81% OR rate for patients with relapsed or refractory MCL The Health Canada approval of Calquence […]readmore
Shots: The FDA’s BT Designation is based on the P-III ELEVATE-TN assessing Calquence (100 mg, bid) as monothx or in combination with obinutuzumab vs chlorambucil + obinutuzumab and in 535 […]readmore
Shots: The BT designation was based on two studies. The P-III ELEVATE-TN (ACE-CL-007) study involves assessing of Calquence as monothx. or in combination with obinutuzumab vs chlorambucil + obinutuzumab in […]readmore
Shots: The P-III ASCEND study results involve assessing of Calquence as monothx. (100mg, bid) vs Rituximab + Idelalisib (IdR) or Bendamustine (BR) in 310 patients in a ratio (1:1) with […]readmore
Copyright © 2020 Digiqole. All Right Reserved.